The authors would particularly like to thank the following individuals for their technical and intellectual contributions to the development of these methods through the years: Bruce Bagwell (Verity Software House), Nad&egrave;ge Bercovici (IDM), Lizanne Breslin (Zynaxis Cell Science and PTI Research), Brian Gray (PTI Research), Jan Fisher (Dartmouth Medical School), Alice Givan (Dartmouth Medical School), Betsy Ohlsson-Wilhelm (SciGro, Inc.), and Mary Waugh (Dartmouth Medical School). They would also like to thank the Bowdoin class of 2006 from the Annual Courses in Research Methods and Applications of Flow Cytometry, which generated the data shown in Figure 2.
Flow cytometry was performed at Roswell Park Cancer Institute's Flow Cytometry Laboratory, which was established in part by equipment grants from the NIH Shared Instrument Program, and receives support from the Core Grant (5 P30 CA016056-29) from the National Cancer Institute to the Roswell Park Cancer Institute, and at the Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory of the University of Pennsylvania, which was established in part by equipment grants from the NIH Shared Instrument Program, and receives support from NIH #2P30 CA016520 from the National Cancer Institute. The work shown in Figures 3 and 5 was also supported in part by SBIR grant EB00228 from the National Institutes of Biomedical Imaging and Bioengineering (NIBIB) awarded to PTI Research, Inc.

1. General Membrane Labeling with PKH26 Cell Tracking Dye (Ref. 25; Figure 1)
<ol>
	<li>Use sterile technique for steps 1.1 - 1.9. Prepare ~107 human peripheral blood mononuclear cells or lymphocytes (hPBMC, hPBL) using the laboratory's standard method with addition of a final 300 x g spin to minimize platelet contamination. Resuspend cells at 107/ml in HBSS+1% BSA and place on ice, reserving a 500 &mu;l aliquot (5x106 cells) for use in Step 2.</li>
	<li>Place 5x106 cells (500 &mu;l) in a 12 x 75 mm conical polypropylene tube. Wash once with 3.5 ml HBSS. Carefully aspirate the supernatant, leaving no more than 15-25 &mu;l of residual fluid, but taking care not to remove cells. Use this tube to prepare a 2x cell suspension in Step 1.4.</li>
	<li>During the cell washing in Step 1.2, add 0.5 ml of Diluent C labeling vehicle (from the PKH26GL kit) to a 12 x 75 mm conical polypropylene tube. Use this tube to prepare a 2x PKH26 solution in Step 1.5.</li>
	<li>Add 0.5 ml of Diluent C labeling vehicle to the washed cell pellet from Step 1.2 and aspirate and dispense 3-4 times to obtain a single cell suspension (2x cells). Avoid bubble formation and excessive mixing, which may reduce cell viability and recovery.</li>
	<li>Immediately after preparing the 2x cell suspension in Step 1.4, prepare a 2x (4 &mu;M) dye solution by adding 2.0 &mu;l of 1.0 mM PKH26 dye stock in ethanol (from the PKH26GL kit) to the Diluent C tube prepared in Step 1.3 and vortex to disperse uniformly.</li>
	<li>Immediately after preparing the 2x dye solution in Step 1.5, rapidly pipette the 2x cell suspension from Step 1.4 into the 2x dye solution and simultaneously aspirate and dispense 3-4 times to completely disperse cells in dye. Do not: add 1.0 mM dye directly to cells; pour 2x cells into 2x dye; or add 2x cells to 2x dye while vortexing. Because staining is nearly instantaneous, such methods yield less uniform intensities than the recommended method (Figure 2).</li>
	<li>After 1 min, add 1.0 ml of heat inactivated serum or HBSS+5% BSA to stop dye uptake into cell membranes. Failure to use enough protein risks the formation of dye aggregates, which can pellet with cells during the washing steps and cause unintended labeling of other cells present in an experiment. If medium with 10% heat inactivated serum (CM) or HBSS+1% BSA is to be used as the stop reagent, carry out staining in a 15 ml conical polypropylene tube and add at least 5.0 ml of stop reagent to insure adsorption of all unincorporated dye.</li>
	<li>Centrifuge the labeled cells for 5 min @ ~400 x g. Carefully aspirate the supernatant without removing cells. Wash the pellet twice with 4 ml of CM or HBSS+1% BSA, dispersing the pellet well before recentrifugation. To minimize carryover of dye adsorbed on tube walls and maximize washing efficiency, transfer the cells to a fresh polypropylene tube after the first resuspension. Note: adequately stained cells will exhibit a distinct pink tinge in the pellet.</li>
	<li>Resuspend the washed cell pellet in 1.0 ml HBSS+1% BSA. Count the cells, determine cell recovery, and adjust volume to give a final concentration of 107/ml. With careful aspiration, cell recovery should be &ge;85%. If cell recovery is &lt; 70%, determine the cause before proceeding further. Withdraw a 150 &mu;l aliquot (1.5x106 cells) and place on ice for use in Step 2.</li>
</ol>
2. Preparation of Instrument and Assay Setup Controls (Table 1)
<ol>
	<li>Aliquot 50 &mu;l (5x105) of unstained cells from the cell suspension saved in Step 1.1 into each of five 1.8 ml Eppendorf tubes: 1, 3, 4, 5, and 7. Aliquot 50 &mu;l (5x105) of PKH26pos cells from Step 1.9 into each of three tubes: 2, 6 and 8.</li>
	<li>Add 10 &mu;l IgG block (100 &mu;g/tube of IgG; see table of Reagents) to Tubes 1-8 and incubate for 10 min at ambient temperature (20-25 &deg;C).</li>
	<li>Add a saturating amount of the antibody(ies) indicated in Table 1 to Tubes 4, 5, 7, and 8 and incubate all samples (Tubes 1-8) for 30 min at ambient temperature and protected from light.</li>
	<li>Add 1.5 ml of HBSS+1% BSA to all samples, pellet the cells by centrifugation (5 min @ 400 x g) and wash once with 1.5 ml of HBSS+1% BSA, with careful aspiration to avoid cell loss.</li>
	<li>Resuspend each sample in 500 &mu;l of HBSS+1% BSA. If required for samples to be analyzed on your cytometer, transfer to a 12 x 75 mm round bottom tube. Add 10 &mu;l of 100 &mu;g/ml 7-AAD daily working stock (see table of Reagents) to Tubes 3, 6, 7 and 8 as indicated in Table 1. Incubate on ice for 30 min prior to use in flow cytometer setup and staining verification (Step 3).</li>
</ol>
3. Flow Cytometer Setup and Staining Verification
<ol>
	<li>Verify that the flow cytometer is operating properly, using the laboratory's established procedures for daily quality control. Verify that signals can readily be detected in each spectral window to be used, and that detector responses are linearly proportional to signal intensity in the window to be used for proliferation monitoring14.</li>
	<li>Acquire FSC vs. SSC data for Tube 1 using linear display scales. Adjust each detector's amplification such that the lymphocyte population falls in the lower left quadrant of the dot plot, is not off-scale in either parameter, and is not interrupted due to thresholding. Collect ungated FSC vs. SSC data for all samples in Steps 3.3 - 3.7.</li>
	<li>Acquire data for Tube 1, using no color compensation and logarithmic display scales for all 4 fluorescence detectors. Adjust each detector's high voltage (HV) to place the autofluorescence of unstained lymphocytes on scale with few/no cells accumulating in the first channel. Set an analysis boundary for each histogram corresponding to the brightest 2% of unstained cells.</li>
	<li>Using no color compensation and the HV settings established in Steps 3.2 and 3.3, acquire data for Tube 2, collecting FSC, SSC and signals in all 4 fluorescence detectors. For the detector used to monitor PKH26 fluorescence, verify that all PKH26pos cells appear on scale as a single symmetrical peak in the 3rd-4th decade, with few/no cells in the last channel. If there are multiple peaks or peak shape is skewed, repeat Step 1 with careful attention to salt minimization and mixing technique (Figure 2). If necessary, adjust dye concentration.</li>
	<li>Using settings established in Step 3.3, acquire data for Tube 3, collecting FSC, SSC and signals in all 4 fluorescence detectors. For the detector used to monitor 7-AAD fluorescence, verify that 7-AADpos cells fall above the 2% boundary established in Step 3.3 (i.e., that non-viable cells are well resolved from viable 7-AADneg cells).</li>
	<li>Using settings established in Step 3.3, acquire data for Tube 4, collecting FSC, SSC and signals in all 4 fluorescence detectors. Verify that CD8pos cells are well resolved from unstained cells (i.e., fall above the 2% boundary established in Step 3.3 for the FITC detector). Repeat with Tube 5 and verify that CD8pos cells are well resolved from unstained cells (i.e. fall above the 2% boundary established in Step 3.3 for the APC detector).</li>
	<li>Using settings established in Step 3.3, acquire data for Tubes 6, 7 and 8, collecting FSC, SSC and signals in all 4 fluorescence detectors.</li>
	<li>Use the list mode files collected for Tubes 1-5 and your color compensation software to establish a color overlap matrix for each fluorochrome in the detectors being used to monitor the three other fluorochromes. Apply this matrix to the list mode file for Sample 6 and verify that the presence of PKH26 labeling does not alter the ability to detect 7-AADpos cells.</li>
	<li>Apply the color overlap matrix from Step 3.8 to the list mode file for Sample 7 and verify that: a) 3 well resolved subpopulations (CD3negCD4neg, CD3posCD4neg and CD3posCD4pos) can be identified on an FITC vs. APC dot plot; and b) the presence of anti-CD3-FITC and anti-CD4-APC does not alter the ability to detect 7-AADpos cells. If the presence of anti-CD3-FITC alters the upper 2% boundary for data collected on the PKH26 detector, readjust the boundary as required.</li>
	<li>Apply the color overlap matrix from Step 3.8 to the list mode file for Sample 8. If the presence of PKH26 labeling alters the 2% boundary for the FITC, 7-AAD or APC detectors from those set using the autofluorescence control in Step 3.3, readjust the boundary(ies) as needed using Tube 7 of Table 1 and verify that it is still possible to distinguish CD3posCD4pos, CD3posCD4neg, and CD3negCD4neg cells using the adjusted boundary(ies).</li>
</ol>
4. Proliferation Model Selection for Cell Division Monitoring by Dye Dilution
<ol>
	<li>Determine the spacing between generations, which is dependent on the number of channels and logarithmic decades on your cytometer. For digital instruments, this value, typically 4 or 5 decades, is determined by the number of bins in the digital signal processor. On analog instruments, where the number of decades is rarely a whole number, accurate modeling requires the precise number of decades to be experimentally determined. To do this, data from a mixture of calibrated fluorescent beads with manufacturer-assigned relative intensities is acquired at the same detector high voltage settings used in the experiment. The position of the bead peaks allows for the calibration of the logarithmic scale in terms of intensity range per log decade. Specifically, this is done by plotting the channel number for each bead type against the log of the manufacturer-assigned value. The slope of a best-fit straight line for the bead data values gives the number of relative intensity units per channel. Multiplied by the number of channels, this value will then be the number of log decades for the full scale, from which the number of channels corresponding to a two-fold decrease in intensity (i.e., daughter generation spacing) can be calculated14.</li>
	<li>Decide whether to use a fixed spacing between generations or to allow the spacing to float. A Standard (fixed) setting will use the generational spacing value determined in Step 4.5 to assign the location of each generation, and is typically used when the histogram lacks distinct peaks. A Float setting allows each generational peak position to be determined by the histogram shape and is typically used when distinguishable generational peaks are evident.</li>
	<li>Decide whether to use a fixed peak width for all generations or a floating width. A fixed width uses the SD calculated for the unstimulated control sample to model all generations and is typically chosen when the sample lacks distinguishable generational peaks. A floating width allows the program to independently vary the SD for each generation and is best used with distinguishable generational peaks.</li>
	<li>Run a program containing a proliferation analysis module (here ModFit LT Version 3.3). Load the stimulated PKH26pos file from the data set to be analyzed (e.g., an stimulated 96 hr culture of PKH26pos cells counterstained as for Tube 8 in Table 1).</li>
	<li>Select the parameters for analysis, in this case PKH26 (585/42) gated on viable (7-AADneg) CD3pos lymphocytes and FSC vs. SSC to exclude small debris and large aggregates (Figure 3). In defining these regions be careful to include the high forward scatter area where blasts are typically found and note that CD3 expression may be down-modulated in stimulated cultures.</li>
	<li>Create a new proliferation model using the Proliferation Wizard. Using the Open Data File (Start tab), load the unstimulated PKH26pos control file and define the location of the peak channel in the parental distribution corresponding to undivided cells.</li>
	<li>Analyze the file for the unstimulated PKH26pos control, noting the values for parental peak position and width (standard deviation). If a fixed peak width (SD) is desired, check Lock SD.</li>
	<li>Load the PKH26neg control (e.g., a 96 hr culture of PKH26neg cells counterstained as for Tube 7 in Table 1). Adjust the number of generations by setting the peak channel for the dimmest generation above the PKH26neg control. This determines the number of daughter generations the model can accurately fit and is typically 6-9 generations.</li>
	<li>Open the data file for the stimulated sample (e.g., a stimulated 96 hr culture of PKH26pos cells counterstained as for Tube 8 in Table 1) and confirm that the regions for the parental peak position and the SD as defined in Step 4.7 remain unchanged. If fixed generational spacing is desired, select Standard model option; otherwise select the Floating option.</li>
	<li>Analyze each experimental file in the data set, using the same model defined in Step 4.9. Minor adjustments to the parental peak position may be necessary for the very best fit as defined both visually and by the reduced chi square (RCS) value.</li>
	<li>Record the desired proliferation metrics resulting from the best-fit for each experimental file in the data set. For a comprehensive description of possible metrics see Ref. 22.</li>
</ol>

<ol>
	<li>Poon, R. Y., Ohlsson-Wilhelm, B. M., Bagwell, C. B., Muirhead, K. A., Diamond, R. A., DeMaggio, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Use+of+PKH+Membrane+Intercalating+Dyes+to+Monitor+Cell+Trafficking+and+Function.">Use of PKH Membrane Intercalating Dyes to Monitor Cell Trafficking and Function.</a> Living Color: Flow Cytometry and Cell Sorting Protocols. , 302-352 (2000).</li><li>Wallace, P. K., Muirhead, K. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cell+Tracking+2007:+A+Proliferation+of+Probes+and+Applications.">Cell Tracking 2007: A Proliferation of Probes and Applications.</a> Immunol. Invest. 36, 527-562 (2007).</li><li>Hawkins, E. D., Hommel, M., Turner, M. L., Battye, F. L., Markham, J. F., Hodgkin, P. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Measuring+lymphocyte+proliferation,+survival+and+differentiation+using+CFSE+time-series+data.">Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data.</a> Nat. Protoc. 2, 2057-2067 (2007).</li><li>Quah, B. J., Warren, H. S., Parish, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Monitoring+lymphocyte+proliferation+in+vitro+and+in+vivo+with+the+intracellular+fluorescent+dye+carboxyfluorescein+diacetate+succinimidyl+ester.">Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester.</a> Nat. Protoc. 2, 2049-2056 (2007).</li><li>Bolton, D. L., Minang, J. T., Trivett, M. T., Song, K., Tuscher, J. J., Li, Y., Piatak, M., O'Connor, D., Lifson, J. D., Roederer, M., Ohlen, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Trafficking,+Persistence,+and+Activation+State+of+Adoptively+Transferred+Allogeneic+and+Autologous+Simian+Immunodeficiency+Virus-Specific+CD8++T+Cell+Clones+during+Acute+and+Chronic+Infection+of+Rhesus+Macaques.">Trafficking, Persistence, and Activation State of Adoptively Transferred Allogeneic and Autologous Simian Immunodeficiency Virus-Specific CD8+ T Cell Clones during Acute and Chronic Infection of Rhesus Macaques.</a> J. Immunol. 184, 303-314 (2010).</li><li>Juopperi, T. A., Sharkis, S. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Isolation+of+Quiescent+Murine+Hematopoietic+Stem+Cells+by+Homing+Properties.">Isolation of Quiescent Murine Hematopoietic Stem Cells by Homing Properties.</a> Meth. Mol. Biol. 430, 21-30 (2008).</li><li>Kusumbe, A. P., Bapat, S. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cancer+stem+cells+and+aneuploid+populations+within+developing+tumors+are+the+major+determinants+of+tumor+dormancy.">Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy.</a> Cancer Res. 69, 9245-9253 (2009).</li><li>Pece, S., Tosonim, D., Confalonieri, S., Mazzarol, G., Vecchi, M., Ronzoni, S., Bernard, L., Viale, G., Pelicci, P. G., Fiore, P. P. D. i. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Biological+and+Molecular+Heterogeneity+of+Breast+Cancers+Correlates+with+Their+Cancer+Stem+Cell+Content.">Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content.</a> Cell. 140, 62-73 (2010).</li><li>Gertner-Dardenne, J., Poupot, M., Gray, B. D., Fourni&#233;, J. -. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lipophilic+fluorochrome+trackers+of+membrane+transfers+between+immune+cells.">Lipophilic fluorochrome trackers of membrane transfers between immune cells.</a> Immunol. Invest. 36, 665-685 (2007).</li><li>Bercovici, N., Givan, A. L., Waugh, M. G., Fisher, J. L., Vernel-Pauillac, F., Ernstoff, M. S., Abastado, J. P., Wallace, P. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multiparameter+precursor+analysis+of+T-cell+responses+to+antigen.">Multiparameter precursor analysis of T-cell responses to antigen.</a> J. Immunol. Methods. 276, 5-17 (2003).</li><li>Givan, A. L., Fisher, J. L., Waugh, M. G., Bercovici, N., Wallace, P. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Use+of+cell-tracking+dyes+to+determine+proliferation+precursor+frequencies+of+antigen-specific+T+cells.">Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells.</a> Methods Mol. Biol. 263, 109-124 (2004).</li><li>Schwaab, T., Tretter, C. P., Gibson, J. J., Cole, B. F., Schned, A. R., Harris, R., Fisher, J. L., Crosby, N., Stempkowski, L. M., Heaney, J. A., Ernstoff, M. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor-related+immunity+in+prostate+cancer+patients+treated+with+human+recombinant+granulocyte+monocyte-colony+stimulating+factor+(GM-CSF).">Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).</a> Prostate. 66 (6), 667-674 (2006).</li><li>Bantly, A. D., Gray, B. D., Breslin, E., Weinstein, E. G., Muirhead, K. A., Ohlsson-Wilhelm, B. M., Moore, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CellVue+Claret,+a+New+Far-Red+Dye,+Facilitates+Polychromatic+Assessment+of+Immune+Cell+Proliferation.">CellVue Claret, a New Far-Red Dye, Facilitates Polychromatic Assessment of Immune Cell Proliferation.</a> Immunol. Invest. 36, 581-605 (2007).</li><li>Givan, A. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+flow+cytometric+assay+for+quantitation+of+rare+antigen-specific+T-cells:+using+cell-tracking+dyes+to+calculate+precursor+frequencies+for+proliferation.">A flow cytometric assay for quantitation of rare antigen-specific T-cells: using cell-tracking dyes to calculate precursor frequencies for proliferation.</a> Immunol. Invest. 36, 563-580 (2007).</li><li>Tario, J. D., Gray, B. D., Wallace, S. S., Muirhead, K. A., Ohlsson-Wilhelm, B. M., Wallace, P. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Novel+lipophilic+tracking+dyes+for+monitoring+cell+proliferation.">Novel lipophilic tracking dyes for monitoring cell proliferation.</a> Immunol Invest. 36, 861-885 (2007).</li><li>Wallace, P. K., Tario, J. D., Fisher, J. L., Wallace, S. S., Ernstoff, M. S., , ., Muirhead, K. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tracking+Antigen-Driven+Responses+by+Flow+Cytometry:+Monitoring+Proliferation+by+Dye+Dilution.">Tracking Antigen-Driven Responses by Flow Cytometry: Monitoring Proliferation by Dye Dilution.</a> Cytometry. 73, 1019-1034 (2008).</li><li>Barth, R. J., Fisher, D. A., Wallace, P. K., Channon, J. Y., Noelle, R. L., Gui, J., Ernstoff, M. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Randomized+Trial+of+Ex+vivo+CD40L+Activation+of+a+Dendritic+Cell+Vaccine+in+Colorectal+Cancer+Patients:+Tumor-Specific+Immune+Responses+Are+Associated+with+Improved+Survival.">A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival.</a> Clin. Cancer Res. 16, 5548-5556 (2010).</li><li>Tario, J. D., Muirhead, K. A., Pan, D., Munson, M., Wallace, P. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tracking+Immune+Cell+Proliferation+and+Cytotoxic+Potential+Using+Flow+Cytometry.">Tracking Immune Cell Proliferation and Cytotoxic Potential Using Flow Cytometry.</a> Meth. Mol. Biol. 699, 119-164 (2011).</li><li>Fuse, S., Underwood, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Simultaneous+Analysis+of+In+Vivo+CD8++T+Cell+Cytotoxicity+Against+Multiple+Epitopes+using+Multicolor+Flow+Cytometry.">Simultaneous Analysis of In Vivo CD8+ T Cell Cytotoxicity Against Multiple Epitopes using Multicolor Flow Cytometry.</a> Immunol. Invest. 36, 829-845 (2007).</li><li>Sch&#252;tz, C., Fleck, M., Mackensen, A., Zoso, A., Halbritter, D., Schneck, J. P., Oelke, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Killer+artificial+antigen-presenting+cells:+a+novel+strategy+to+delete+specific+T+cells.">Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.</a> Blood. 111, 3546-3552 (2008).</li><li>Zaritskaya, L., Shurin, M. R., Sayers, T. J., Malyguine, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=New+flow+cytometric+assays+for+monitoring+cell-mediated+cytotoxicity.">New flow cytometric assays for monitoring cell-mediated cytotoxicity.</a> Expert Rev. Vaccines. 9, 601-616 (2010).</li><li>Roederer, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Interpretation+of+cellular+proliferation+data:+Avoid+the+panglossian.">Interpretation of cellular proliferation data: Avoid the panglossian.</a> Cytometry. 79A, 95-101 (2011).</li><li>Quah, B. J. C., Parish, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Use+of+Carboxyfluorescein+Diacetate+Succinimidyl+Ester+(CFSE)+to+Monitor+Lymphocyte+Proliferation.">The Use of Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) to Monitor Lymphocyte Proliferation.</a> J. Vis. Exp. (44), e2259 (2010).</li><li>Houlihan, D. D., Newsome, P. N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Critical+Review+of+Clinical+Trials+of+Bone+Marrow+Stem+Cells+in+Liver+Disease.">Critical Review of Clinical Trials of Bone Marrow Stem Cells in Liver Disease.</a> Gastroenterology. 135, 438-450 (2008).</li><li>Brusko, T. M., Hulme, M. A., Myhr, C. B., Haller, M. J., Atkinson, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Assessing+the+In+Vitro+Suppressive+Capacity+of+Regulatory.">Assessing the In Vitro Suppressive Capacity of Regulatory.</a> T Cells. Immunol. Invest. 36, 607-628 (2007).</li></ol>

K. Humphrey, J.D. Tario, Jr. and P.K. Wallace have received pre-commercial cell tracking reagents for evaluation from Life Technologies, Inc. and BD Biosciences. A.D. Bantly and J.S. Moore have received pre-commercial cell tracking reagents for evaluation from Life Technologies, Inc. and funding from PTI Research, Inc. for pre-commercial characterization of various CellVue cell tracking dyes. K. Muirhead is employed by SciGro, Inc., which provides consulting services to Phanos Technologies, Inc. (owner of the PKH and CellVue dyes) and provides backup technical support for Sigma-Aldrich and Molecular Targeting Technologies, Inc. (distributors of these dyes). Production and Free Access to this article is sponsored by Sigma-Aldrich.

The methods described here are those found in our combined laboratories to most reliably give optimal results for hPBMC labeling using membrane dyes13,16,18 and for lymphocyte subset phenotyping and proliferation tracking using either membrane or protein dyes2,11,13,16,18. As illustrated in Figures 1 and 2, bright uniform labeling is most readily achieved by limiting the presence of physiologic salts and using a mixing technique that results in rapid, homogeneous exposure of all cells to the same concentration of dye. Because staining with membrane dyes occurs by partitioning into the lipid bilayer, other variables that alter free dye concentration can also impact labeling efficiency. For example, labeling in round bottom polystyrene tubes results in less efficient washout of salts prior to resuspension in Diluent C and also in reduced free dye concentration due to dye adsorption on tube walls, particularly at lower dye concentrations. Both factors tend to give broader staining distributions than when labeling is done using conical bottom polypropylene tubes (Figures 3, 4 and unpublished results). Sample age and type can also affect peak width even when optimized staining procedures are used. For example, CVs for PKH26pos lymphocytes isolated from freshly drawn blood range from 14-20% (Figure 3, Ref. 13 and unpublished results) whereas CVs for lymphocytes isolated from 24 hr old blood samples or TRIMA pheresis filters range from 25-30% (Figure 4 and Ref. 18).
Staining uniformity and the extent to which non-viable cells can be excluded from analysis both affect whether distinguishable daughter peaks are evident in the dye dilution profile, which in turn affects choice of a proliferation model to fit the observed data (Figures 5 and 6). Although ModFit (Verity Software House, Topsham, ME) is used here as an example of software used to generate metrics such as Proliferation Index and Precursor Frequency (Figures 3, 5 and 6; Table 3), other software packages also contain modules to analyze proliferation data. These include FCSExpress (De Novo Software, Los Angeles, CA) and FlowJo (Tree Star, Inc., Ashland, OR). All of these programs use a non-linear least squares analysis to iteratively find the best fit to the raw data by changing the position, height and SD (or width) of Gaussian peaks representing sequential daughter generations. Proliferative Index (PI) and Precursor Frequency (PF) are the most commonly used measures of extent of proliferation. PI, as defined by ModFit, is a measure of the increase in cell number over the course of the assay, analogous to the 'stimulation index' of a thymidine uptake assay. PF returns the fraction of cells in the initial population that responded to the stimulus by proliferating. Caution is advised, however, when reading the literature since terminology varies somewhat among software packages (e.g., FlowJo and ModFit use different definitions and calculations for what is meant by "Proliferation Index")22.
The critical issues discussed here for labeling and proliferation analysis with membrane dyes are also encountered when using protein dyes. For example, careful attention to mixing technique must also be observed, along with exclusion of dead/dying cells, in order to obtain uniform distributions and distinguishable daughter peaks when using CFSE (Figure 6)2-4,13,18,24. Appropriate choice of fluorochromes for phenotyping and viability assessment is also important to avoid excessive spectral overlap and inability to recognize antibody positive cells, particularly with visible emitting protein dyes such as CFSE2-4,11,13,16,18. Reducing the concentration of tracking dye decreases compensation problems in adjacent spectral channels but also limits the number of cell divisions that can be monitored before daughter cell intensities begin to overlap with autofluorescence. Alternatively, use of newer cell tracking dyes such as the far red emitting CellVue Claret (Sigma-Aldrich, St. Louis, MO) or violet emitting CellTrace Violet (Life Technologies, Grand Island, NY) may reduce compensation problems (Figure 6). Finally, although membrane dyes generally tend to exhibit less toxicity11,26, it is possible to over-label cells with either class of dye. It is therefore always necessary to verify that the concentration of tracking dye used has not altered the functionality of the cells to be tracked (Figure 6)3,13,16,18.

<table border="1">
	<tbody>
		<tr>
			<td>Reagent or equipment</td>
			<td>Company</td>
			<td>Catalogue number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>Commercially Purchased</td>
		</tr>
		<tr>
			<td>7-Aminoactinomycin D</td>
			<td>Sigma-Aldrich</td>
			<td>A9400</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Bovine serum albumin (BSA)</td>
			<td>Sigma-Aldrich</td>
			<td>A4503</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Fetal bovine serum (FBS)</td>
			<td>Atlanta Biologicals</td>
			<td>S11150</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Hanks balanced salt solution (HBSS)</td>
			<td>Life Technologies</td>
			<td>14175-079</td>
			<td>Calcium and magnesium free, without phenol red</td>
		</tr>
		<tr>
			<td>Human IgG Cohn fraction II and III globulins</td>
			<td>Sigma-Aldrich</td>
			<td>G-4386</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD3-FITC</td>
			<td>BD Biosciences</td>
			<td>349201</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD4-APC</td>
			<td>BD Biosciences</td>
			<td>340672</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD4-PECy7</td>
			<td>BD Biosciences</td>
			<td>348799</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD8-FITC</td>
			<td>BD Biosciences</td>
			<td>347313</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD8-APC</td>
			<td>Caltag (Life Technologies)</td>
			<td>MHCD0805</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD19-APC</td>
			<td>Caltag (Life Technologies)</td>
			<td>MHCD1905</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD25-APC</td>
			<td>BD Biosciences</td>
			<td>340938</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD127-PE</td>
			<td>BD Biosciences</td>
			<td>557938</td>
			<td>Saturating concentration as determined by laboratory titration</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD3</td>
			<td>eBiosciences</td>
			<td>16-0037-85</td>
			<td>1.0 mg/ml; azide free</td>
		</tr>
		<tr>
			<td>Mouse anti-human CD28</td>
			<td>eBiosciences</td>
			<td>16-0289-85</td>
			<td>1.0 mg/ml; azide free</td>
		</tr>
		<tr>
			<td>PBS</td>
			<td>Gibco</td>
			<td>21300-058</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>PKH26 red fluorescent cell linker kit containing 10-3M PKH26 in EtOH and Diluent C</td>
			<td>Sigma-Aldrich</td>
			<td>PKH26GL-1KT 
			or 
			MINI26-1KT</td>
			<td>Procedures in Step 1 also apply to kits containing PKH67 or other CellVue dyes</td>
		</tr>
		<tr>
			<td>CellVue Claret far red fluorescent cell linker kit containing 10-3M CellVue Claret in EtOH and Diluent C</td>
			<td>Sigma-Aldrich</td>
			<td>MINCLARET-1KT or MIDCLARET-1KT</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE)</td>
			<td>Invitrogen (Life Technologies)</td>
			<td>C34554</td>
			<td>Non-fluorescent; cleaved by membrane esterases to form fluorescent amino-reactive carboxyfluorescein succinimidyl ester (CFSE)</td>
		</tr>
		<tr>
			<td>LIVE/DEAD Fixable Violet</td>
			<td>Invitrogen (Life Technologies)</td>
			<td>L34955</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Sterile 12 x 75 mm conical 
			polypropylene tubes &amp; caps</td>
			<td>VWR</td>
			<td>60818-102</td>
			<td>Gives better membrane dye staining efficiency (reduced dye adsorption; less cell loss during supernatant aspiration)</td>
		</tr>
		<tr>
			<td>12 x 75 mm round bottom 
			polystyrene tubes</td>
			<td>Becton Dickinson</td>
			<td>21008-936</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Flow cytometer</td>
			<td>BD Bioscience</td>
			<td>FACSCalibur 
			LSRFortessa</td>
			<td>Any cytometer able to detect FITC, PKH26, and 7-AAD (ex. 488 nm; em. 520 nm, 567 nm, and 655 nm, respectively) and APC ex. 633-640 nm; em. 660 nm)</td>
		</tr>
		<tr>
			<td>Flow cytometer</td>
			<td>Beckman Coulter</td>
			<td>LSRII CyAn</td>
			<td>Any cytometer able to detect FITC, PKH26, and 7-AAD (ex. 488 nm; em. 520 nm, 567 nm, and 655 nm, respectively) and APC ex. 633-640 nm; em. 660 nm)</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>Laboratory Prepared</td>
		</tr>
		<tr>
			<td>7-Aminoactinomycin D, 
			concentrated stock</td>
			<td>NA</td>
			<td>NA</td>
			<td>1 mg/ml in PBS. Freeze in aliquots and store at -20 &deg;C.</td>
		</tr>
		<tr>
			<td>7-Aminoactinomycin D, 
			working stock</td>
			<td>NA</td>
			<td>NA</td>
			<td>100 &mu;g/ml in PBS; prepare daily from 1 mg/ml frozen stock.</td>
		</tr>
		<tr>
			<td>IgG block</td>
			<td>NA</td>
			<td>NA</td>
			<td>HBSS + 10 mg/ml Human IgG Cohn fraction II and III globulins + 10 mg/ml BSA.</td>
		</tr>
	</tbody>
</table>

optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes

Fluorescent cell tracking dyes, in combination with flow and image cytometry, are powerful tools with which to study the interactions and fates of different cell types in vitro and in vivo.1-5 Although there are literally thousands of publications using such dyes, some of the most commonly encountered cell tracking applications include monitoring of:
<ol>
	<li>stem and progenitor cell quiescence, proliferation and/or differentiation6-8</li>
	<li>antigen-driven membrane transfer9 and/or precursor cell proliferation3,4,10-18 and</li>
	<li>immune regulatory and effector cell function1,18-21.</li>
</ol>
Commercially available cell tracking dyes vary widely in their chemistries and fluorescence properties but the great majority fall into one of two classes based on their mechanism of cell labeling. "Membrane dyes", typified by PKH26, are highly lipophilic dyes that partition stably but non-covalently into cell membranes1,2,11. "Protein dyes", typified by CFSE, are amino-reactive dyes that form stable covalent bonds with cell proteins4,16,18. Each class has its own advantages and limitations. The key to their successful use, particularly in multicolor studies where multiple dyes are used to track different cell types, is therefore to understand the critical issues enabling optimal use of each class2-4,16,18,24.
The protocols included here highlight three common causes of poor or variable results when using cell-tracking dyes. These are:
<ol>
	<li>Failure to achieve bright, uniform, reproducible labeling. This is a necessary starting point for any cell tracking study but requires attention to different variables when using membrane dyes than when using protein dyes or equilibrium binding reagents such as antibodies.</li>
	<li>Suboptimal fluorochrome combinations and/or failure to include critical compensation controls. Tracking dye fluorescence is typically 102 - 103 times brighter than antibody fluorescence. It is therefore essential to verify that the presence of tracking dye does not compromise the ability to detect other probes being used.</li>
	<li>Failure to obtain a good fit with peak modeling software. Such software allows quantitative comparison of proliferative responses across different populations or stimuli based on precursor frequency or other metrics. Obtaining a good fit, however, requires exclusion of dead/dying cells that can distort dye dilution profiles and matching of the assumptions underlying the model with characteristics of the observed dye dilution profile.</li>
</ol>
Examples given here illustrate how these variables can affect results when using membrane and/or protein dyes to monitor cell proliferation.

Watch this Scientific Journal Video about Optimized Staining and Proliferation Modeling Methods for Cell Division Monitoring using Cell Tracking Dyes at JoVE.com

Optimized Staining and Proliferation Modeling Methods for Cell Division Monitoring using Cell Tracking Dyes

Successful use of cell tracking dyes to monitor immune cell function and proliferation involves several critical steps. We describe methods for: 1) obtaining bright, uniform, reproducible label-ing with membrane dyes; 2) selecting fluorochromes and data acquisition conditions; and 3) choosing a model to quantify cell proliferation based on dye dilution.

Fluorescent cell tracking dyes, in combination with flow and image cytometry, are powerful tools with which to study the interactions and fates of ...

optimized-staining-proliferation-modeling-methods-for-cell-division

Research

JoVE Journal

Biology

35.2K 조회수.  Roswell Park Cancer Institute. 면역 세포 기능과 확산을 모니터하기위한 셀 추적 염료의 성공적인 사용은 몇 가지 중요한 단계를 포함한다. 우리가 방법을 설명합니다 : 1) 막 염료를 갖춘 밝고 균일 재현 라벨 - ING 획득, 2) fluorochromes 및 데이터 수집 조건을 선택을하고, 3) 염료 희석에 따라 세포 증식을 수량화 할 수있는 모델을 선택.